Portal:RareDisease/FeaturedPathways
From WikiPathways
(Difference between revisions)
Current revision (11:39, 2 June 2021) (view source) |
|||
(31 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
+ | == Rare diseases in general == | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px | + | |width=100px|{{#pwImage:Pathway:WP2059|250px||Alzheimers Disease}} |
|width=100px|{{#pwImage:Pathway:WP2447|250px||Amyotrophic lateral sclerosis (ALS) (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP2447|250px||Amyotrophic lateral sclerosis (ALS) (Homo sapiens)}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP3853|250px||ERK Pathway in Huntington's Disease}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4803|250px||Ciliopathies}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP3569|250px||Fanconi Anemia Pathway (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3569|250px||Fanconi Anemia Pathway (Homo sapiens)}} | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4549|250px||Fragile X Syndrome}} |
- | | | + | |width=100px|{{#pwImage:Pathway:WP4656|250px||Joubert Syndrome}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP3584|250px||MECP2 and Associated Rett Syndrome (Homo sapiens)}} |
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4540|250px||Pathways Regulating Hippo Signaling}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP2371|250px||Parkinsons Disease Pathway}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4541|250px||po-Merlin Signaling Dysregulation}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP3995|250px||Prion disease pathway}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4312|250px||Rett syndrome causing genes}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4746|250px||Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism}} | ||
|width=100px|{{#pwImage:Pathway:WP4298|250px||Viral Acute Myocarditis (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4298|250px||Viral Acute Myocarditis (Homo sapiens)}} | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4577|250px||Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway}} |
- | + | ||
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4947|250px||Nitric oxide metabolism in cystic fibrosis}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5087|250px||Malignant pleural mesothelioma}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4804|250px||Cholesterol biosynthesis with skeletal dysplasias}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5114|250px||Nucleotide excision repair in xeroderma pigmentosum}} |
|} | |} | ||
+ | |||
+ | == Copy number variation syndromes == | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4905|250px||1q21.1 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4906|250px||3q29 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4657|250px||22q11.2 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP3998|250px||Prader-Willi and Angelman Syndrome}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4932|250px||7q11.23 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4940|250px||15q11.2 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4942|250px||15q13.3 copy number variation syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4949|250px||16p11.2 proximal deletion syndrome}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4950|250px||16p11.2 distal deletion syndrome}} | ||
+ | |} | ||
+ | |||
+ | == Laminopathies == | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4879|250px||Interacting Laminopathic Pathways}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4299|250px||Lamin A-processing pathway (Homo sapiens)}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4320|250px||The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome (Homo sapiens)}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4844|250px||The influence of laminopathies on Wnt signaling}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4535|250px||Envelope proteins and their potential roles in EDMD physiopathology}} | ||
+ | |} | ||
+ | |||
+ | == Disorders of sex development == | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4673|250px||Genes involved in male infertility}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4871|250px||Kisspeptin/Kisspeptin Receptor System in the Ovary}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4842|250px||Mammalian disorder of sexual development}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4835|250px||Peroxiredoxin 2 induced ovarian failure}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4814|250px||Somatic Sex determination}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4524|250px||The alternative pathway of fetal androgen synthesis}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5074|250px||Kallmann syndrome}} | ||
+ | |} | ||
+ | == CAKUT (congenital anomalies of the kidney and urinary tract)== | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP5053|250px||Development of uretric collection system}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4830|250px||GDNF/RET signalling axis}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4823|250px||Genes controlling renal nephrogenesis}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5052|250px||Nephrogenesis}} | ||
+ | |} | ||
+ | |||
+ | == Lipodystrophy, dyslipidemia and hyperlipidemia == | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP5105|250px||Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5108|250px||Familial hyperlipidemia type 1}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5109|250px||Familial hyperlipidemia type 2}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5110|250px||Familial hyperlipidemia type 3}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP5111|250px||Familial hyperlipidemia type 4}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5112|250px||Familial hyperlipidemia type 5}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5104|250px||Acquired partial lipodystrophy / Barraquer-Simons syndrome}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5103|250px||Progeria-associated lipodystrophy}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP5102|250px||Familial partial lipodystrophy (FPLD)}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP5101|250px||Congenital generalized lipodystrophy (CGL)}} | ||
+ | |} | ||
+ | |||
+ | == Inborn errors of metabolism == | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP4507|250px||Molybdenum (Moco) cofactor biosynthesis}} | |width=100px|{{#pwImage:Pathway:WP4507|250px||Molybdenum (Moco) cofactor biosynthesis}} | ||
Line 21: | Line 103: | ||
|width=100px|{{#pwImage:Pathway:WP4271|250px||Vitamin B12 Disorders}} | |width=100px|{{#pwImage:Pathway:WP4271|250px||Vitamin B12 Disorders}} | ||
|width=100px|{{#pwImage:Pathway:WP4297|250px||Thiamine Disorders}} | |width=100px|{{#pwImage:Pathway:WP4297|250px||Thiamine Disorders}} | ||
+ | |} | ||
+ | {| style="margin: 10px" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4292|250px||Methionine metabolism leading to sulfur amino acids and related disorders}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4259|250px||Disorders of Folate Metabolism and Transport}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4288|250px||MTHFR deficiency (additonal pathway)}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4228|250px||Vitamine B6-Dependent and Responsive Disorders}} | ||
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP4236|250px||Disorders of the Krebs Cycle}} | |width=100px|{{#pwImage:Pathway:WP4236|250px||Disorders of the Krebs Cycle}} | ||
- | |width=100px|{{#pwImage:Pathway:WP4153|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4153|250px||Degradation pathway of sphingolipids, including diseases}} |
|width=100px|{{#pwImage:Pathway:WP4220|250px||Neurotransmitter Disorders}} | |width=100px|{{#pwImage:Pathway:WP4220|250px||Neurotransmitter Disorders}} | ||
|width=100px|{{#pwImage:Pathway:WP4224|250px||Purine Disorders}} | |width=100px|{{#pwImage:Pathway:WP4224|250px||Purine Disorders}} | ||
Line 30: | Line 118: | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP4225|250px||Pyrimidine Disorders}} | |width=100px|{{#pwImage:Pathway:WP4225|250px||Pyrimidine Disorders}} | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4156|250px||Disorders of Phenylalanine and Tetrahydrobiopterin (BH4) Metabolism}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4506|250px||Tyrosine Metabolism}} |
|width=100px|{{#pwImage:Pathway:WP4518|250px||Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases}} | |width=100px|{{#pwImage:Pathway:WP4518|250px||Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases}} | ||
|} | |} | ||
Line 41: | Line 129: | ||
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4792|250px||Purine metabolism}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4545|250px||Oxysterols derived from cholesterol}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4595|250px||Urea cycle and associated pathways}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5029|250px||Amino acid transport defects}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4686|250px||Leucine, isoleucine and valine metabolism}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5028|250px||Glycine metabolism, including IEMs}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4157|250px||GABA metabolism (aka GHB)}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5026|250px||Proline and hydroxyproline pathways}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4686|250px||Leucine, isoleucine and valine metabolism}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5028|250px||Glycine metabolism, including IEMs}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4157|250px||GABA metabolism (aka GHB)}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5026|250px||Proline and hydroxyproline pathways}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4688|250px||Serine metabolism}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5031|250px||Biotin metabolism, including IEMs}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5037|250px||Riboflavin and CoQ disorders}} |
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4971|250px||Phosphoinositides metabolism}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5030|250px||Ethylmalonic encephalopathy}} |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
|} | |} | ||
List of featured pathways: | List of featured pathways: | ||
- | * [[Pathway: | + | * [[Pathway:WP2059]] - Alzheimers Disease |
+ | * [[Pathway:WP2371]] - Parkinsons Disease Pathway | ||
* [[Pathway:WP2447]] - Amyotrophic lateral sclerosis (ALS) | * [[Pathway:WP2447]] - Amyotrophic lateral sclerosis (ALS) | ||
* [[Pathway:WP3569]] - Fanconi Anemia Pathway | * [[Pathway:WP3569]] - Fanconi Anemia Pathway | ||
- | * [[Pathway: | + | * [[Pathway:WP3584]] - MECP2 and Associated Rett Syndrome |
- | * [[Pathway: | + | * [[Pathway:WP3853]] - ERK Pathway in Huntington's Disease |
- | * [[Pathway: | + | * [[Pathway:WP3995]] - Prion disease pathway |
+ | * [[Pathway:WP3998]] - Prader-Willi and Angelman Syndrome | ||
+ | * [[Pathway:WP4153]] - Degradation pathway of sphingolipids, including diseases | ||
* [[Pathway:WP4156]] - Disorders of Phenylalanine and Tetrahydrobiopterin | * [[Pathway:WP4156]] - Disorders of Phenylalanine and Tetrahydrobiopterin | ||
- | * [[Pathway: | + | * [[Pathway:WP4157]] - GABA metabolism (aka GHB) |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
* [[Pathway:WP4220]] - Neurotransmitter Disorders | * [[Pathway:WP4220]] - Neurotransmitter Disorders | ||
* [[Pathway:WP4224]] - Purine Disorders | * [[Pathway:WP4224]] - Purine Disorders | ||
* [[Pathway:WP4225]] - Pyrimidine Disorder | * [[Pathway:WP4225]] - Pyrimidine Disorder | ||
- | * [[Pathway: | + | * [[Pathway:WP4228]] - Vitamine B6-Dependent and Responsive Disorders |
- | * [[Pathway: | + | * [[Pathway:WP4236]] - Disorders of the Krebs Cycle |
+ | * [[Pathway:WP4259]] - Disorders of Folate Metabolism and Transport | ||
+ | * [[Pathway:WP4271]] - Vitamin B12 Disorders | ||
+ | * [[Pathway:WP4288]] - MTHFR deficiency | ||
+ | * [[Pathway:WP4292]] - Methionine metabolism leading to sulfur amino acids and related disorders | ||
+ | * [[Pathway:WP4297]] - Thiamine Disorders | ||
+ | * [[Pathway:WP4298]] - Viral Acute Myocarditis | ||
+ | * [[Pathway:WP4299]] - Lamin A-processing pathway | ||
+ | * [[Pathway:WP4312]] - Rett syndrome causing genes | ||
+ | * [[Pathway:WP4320]] - The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome | ||
+ | * [[Pathway:WP4504]] - Cysteine and Methionine catabolism | ||
+ | * [[Pathway:WP4506]] - Tyrosine Metabolism | ||
+ | * [[Pathway:WP4507]] - Molybdenum (Moco) cofactor biosynthesis | ||
* [[Pathway:WP4518]] - Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases | * [[Pathway:WP4518]] - Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases | ||
* [[Pathway:WP4519]] - Cerebral Organic Acidurias | * [[Pathway:WP4519]] - Cerebral Organic Acidurias | ||
Line 106: | Line 191: | ||
* [[Pathway:WP4523]] - Classical pathway of steroidogenesis, including diseases | * [[Pathway:WP4523]] - Classical pathway of steroidogenesis, including diseases | ||
* [[Pathway:WP4524]] - The alternative pathway of fetal androgen synthesis | * [[Pathway:WP4524]] - The alternative pathway of fetal androgen synthesis | ||
- | |||
- | |||
- | |||
- | |||
- | |||
* [[Pathway:WP4535]] - Envelope proteins and their potential roles in EDMD physiopathology | * [[Pathway:WP4535]] - Envelope proteins and their potential roles in EDMD physiopathology | ||
- | * [[Pathway: | + | * [[Pathway:WP4540]] - Pathways Regulating Hippo Signaling |
- | * [[Pathway: | + | * [[Pathway:WP4541]] - po-Merlin Signaling Dysregulation |
- | * [[Pathway: | + | * [[Pathway:WP4545]] - Oxysterols derived from cholesterol |
+ | * [[Pathway:WP4549]] - Fragile X Syndrome | ||
+ | * [[Pathway:WP4577]] - Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway | ||
+ | * [[Pathway:WP4595]] - Urea cycle and associated pathways | ||
* [[Pathway:WP4656]] - Joubert Syndrome | * [[Pathway:WP4656]] - Joubert Syndrome | ||
- | * [[Pathway: | + | * [[Pathway:WP4657]] - 22q11.2 Deletion Syndrome |
* [[Pathway:WP4673]] - Genes involved in male infertility | * [[Pathway:WP4673]] - Genes involved in male infertility | ||
- | * [[Pathway: | + | * [[Pathway:WP4686]] - Leucine, isoleucine and valine metabolism |
- | * [[Pathway: | + | * [[Pathway:WP4688]] - Serine metabolism |
- | * [[Pathway: | + | * [[Pathway:WP4746]] - Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
* [[Pathway:WP4792]] - Purine metabolism | * [[Pathway:WP4792]] - Purine metabolism | ||
- | * [[Pathway: | + | * [[Pathway:WP4803]] - Ciliopathies |
+ | * [[Pathway:WP4804]] - Cholesterol biosynthesis with skeletal dysplasias | ||
* [[Pathway:WP4814]] - Somatic Sex determination | * [[Pathway:WP4814]] - Somatic Sex determination | ||
+ | * [[Pathway:WP4823]] - Genes controlling renal nephrogenesis | ||
+ | * [[Pathway:WP4830]] - GDNF/RET signalling axis | ||
+ | * [[Pathway:WP4835]] - Peroxiredoxin 2 induced ovarian failure | ||
+ | * [[Pathway:WP4842]] - Mammalian disorder of sexual development | ||
+ | * [[Pathway:WP4844]] - The influence of laminopathies on Wnt signaling | ||
+ | * [[Pathway:WP4871]] - Kisspeptin/Kisspeptin Receptor System in the Ovary | ||
+ | * [[Pathway:WP4879]] - Interacting Laminopathic Pathways | ||
+ | * [[Pathway:WP4905]] - 1q21.1 copy number variation syndrome | ||
+ | * [[Pathway:WP4906]] - 3q29 copy number variation syndrome | ||
+ | * [[Pathway:WP4932]] - 7q11.23 copy number variation syndrome | ||
+ | * [[Pathway:WP4940]] - 15q11.2 copy number variation syndrome | ||
+ | * [[Pathway:WP4942]] - 15q13.3 copy number variation syndrome | ||
+ | * [[Pathway:WP4947]] - Nitric oxide metabolism in cystic fibrosis | ||
+ | * [[Pathway:WP4949]] - 16p11.2 proximal deletion syndrome | ||
+ | * [[Pathway:WP4950]] - 16p11.2 distal deletion syndrome | ||
+ | * [[Pathway:WP4971]] - Phosphoinositides metabolism | ||
+ | * [[Pathway:WP5026]] - Proline and hydroxyproline pathways | ||
+ | * [[Pathway:WP5028]] - Glycine metabolism, including IEMs | ||
+ | * [[Pathway:WP5029]] - Amino acid transport defects | ||
+ | * [[Pathway:WP5030]] - Ethylmalonic encephalopathy | ||
+ | * [[Pathway:WP5031]] - Biotin metabolism, including IEMs | ||
+ | * [[Pathway:WP5037]] - Riboflavin and CoQ disorders | ||
+ | * [[Pathway:WP5052]] - Nephrogenesis | ||
+ | * [[Pathway:WP5053]] - Development of uretric collection system | ||
+ | * [[Pathway:WP5074]] - Kallmann syndrome | ||
+ | * [[Pathway:WP5087]] - Malignant pleural mesothelioma | ||
+ | * [[Pathway:WP5101]] - Congenital generalized lipodystrophy (CGL) | ||
+ | * [[Pathway:WP5102]] - Familial partial lipodystrophy (FPLD) | ||
+ | * [[Pathway:WP5103]] - Progeria-associated lipodystrophy | ||
+ | * [[Pathway:WP5104]] - Acquired partial lipodystrophy / Barraquer-Simons syndrome | ||
+ | * [[Pathway:WP5105]] - Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia | ||
+ | * [[Pathway:WP5108]] - Familial hyperlipidemia type 1 | ||
+ | * [[Pathway:WP5109]] - Familial hyperlipidemia type 2 | ||
+ | * [[Pathway:WP5110]] - Familial hyperlipidemia type 3 | ||
+ | * [[Pathway:WP5111]] - Familial hyperlipidemia type 4 | ||
+ | * [[Pathway:WP5112]] - Familial hyperlipidemia type 5 | ||
+ | * [[Pathway:WP5114]] - Nucleotide excision repair in xeroderma pigmentosum |
Current revision
Contents |
Rare diseases in general
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Copy number variation syndromes
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Laminopathies
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Disorders of sex development
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
CAKUT (congenital anomalies of the kidney and urinary tract)
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Lipodystrophy, dyslipidemia and hyperlipidemia
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Inborn errors of metabolism
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
List of featured pathways:
- Pathway:WP2059 - Alzheimers Disease
- Pathway:WP2371 - Parkinsons Disease Pathway
- Pathway:WP2447 - Amyotrophic lateral sclerosis (ALS)
- Pathway:WP3569 - Fanconi Anemia Pathway
- Pathway:WP3584 - MECP2 and Associated Rett Syndrome
- Pathway:WP3853 - ERK Pathway in Huntington's Disease
- Pathway:WP3995 - Prion disease pathway
- Pathway:WP3998 - Prader-Willi and Angelman Syndrome
- Pathway:WP4153 - Degradation pathway of sphingolipids, including diseases
- Pathway:WP4156 - Disorders of Phenylalanine and Tetrahydrobiopterin
- Pathway:WP4157 - GABA metabolism (aka GHB)
- Pathway:WP4220 - Neurotransmitter Disorders
- Pathway:WP4224 - Purine Disorders
- Pathway:WP4225 - Pyrimidine Disorder
- Pathway:WP4228 - Vitamine B6-Dependent and Responsive Disorders
- Pathway:WP4236 - Disorders of the Krebs Cycle
- Pathway:WP4259 - Disorders of Folate Metabolism and Transport
- Pathway:WP4271 - Vitamin B12 Disorders
- Pathway:WP4288 - MTHFR deficiency
- Pathway:WP4292 - Methionine metabolism leading to sulfur amino acids and related disorders
- Pathway:WP4297 - Thiamine Disorders
- Pathway:WP4298 - Viral Acute Myocarditis
- Pathway:WP4299 - Lamin A-processing pathway
- Pathway:WP4312 - Rett syndrome causing genes
- Pathway:WP4320 - The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome
- Pathway:WP4504 - Cysteine and Methionine catabolism
- Pathway:WP4506 - Tyrosine Metabolism
- Pathway:WP4507 - Molybdenum (Moco) cofactor biosynthesis
- Pathway:WP4518 - Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases
- Pathway:WP4519 - Cerebral Organic Acidurias
- Pathway:WP4521 - Glycosylation and related congenital defects
- Pathway:WP4522 - Metabolic pathway of LDL, HDL and TG
- Pathway:WP4523 - Classical pathway of steroidogenesis, including diseases
- Pathway:WP4524 - The alternative pathway of fetal androgen synthesis
- Pathway:WP4535 - Envelope proteins and their potential roles in EDMD physiopathology
- Pathway:WP4540 - Pathways Regulating Hippo Signaling
- Pathway:WP4541 - po-Merlin Signaling Dysregulation
- Pathway:WP4545 - Oxysterols derived from cholesterol
- Pathway:WP4549 - Fragile X Syndrome
- Pathway:WP4577 - Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway
- Pathway:WP4595 - Urea cycle and associated pathways
- Pathway:WP4656 - Joubert Syndrome
- Pathway:WP4657 - 22q11.2 Deletion Syndrome
- Pathway:WP4673 - Genes involved in male infertility
- Pathway:WP4686 - Leucine, isoleucine and valine metabolism
- Pathway:WP4688 - Serine metabolism
- Pathway:WP4746 - Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism
- Pathway:WP4792 - Purine metabolism
- Pathway:WP4803 - Ciliopathies
- Pathway:WP4804 - Cholesterol biosynthesis with skeletal dysplasias
- Pathway:WP4814 - Somatic Sex determination
- Pathway:WP4823 - Genes controlling renal nephrogenesis
- Pathway:WP4830 - GDNF/RET signalling axis
- Pathway:WP4835 - Peroxiredoxin 2 induced ovarian failure
- Pathway:WP4842 - Mammalian disorder of sexual development
- Pathway:WP4844 - The influence of laminopathies on Wnt signaling
- Pathway:WP4871 - Kisspeptin/Kisspeptin Receptor System in the Ovary
- Pathway:WP4879 - Interacting Laminopathic Pathways
- Pathway:WP4905 - 1q21.1 copy number variation syndrome
- Pathway:WP4906 - 3q29 copy number variation syndrome
- Pathway:WP4932 - 7q11.23 copy number variation syndrome
- Pathway:WP4940 - 15q11.2 copy number variation syndrome
- Pathway:WP4942 - 15q13.3 copy number variation syndrome
- Pathway:WP4947 - Nitric oxide metabolism in cystic fibrosis
- Pathway:WP4949 - 16p11.2 proximal deletion syndrome
- Pathway:WP4950 - 16p11.2 distal deletion syndrome
- Pathway:WP4971 - Phosphoinositides metabolism
- Pathway:WP5026 - Proline and hydroxyproline pathways
- Pathway:WP5028 - Glycine metabolism, including IEMs
- Pathway:WP5029 - Amino acid transport defects
- Pathway:WP5030 - Ethylmalonic encephalopathy
- Pathway:WP5031 - Biotin metabolism, including IEMs
- Pathway:WP5037 - Riboflavin and CoQ disorders
- Pathway:WP5052 - Nephrogenesis
- Pathway:WP5053 - Development of uretric collection system
- Pathway:WP5074 - Kallmann syndrome
- Pathway:WP5087 - Malignant pleural mesothelioma
- Pathway:WP5101 - Congenital generalized lipodystrophy (CGL)
- Pathway:WP5102 - Familial partial lipodystrophy (FPLD)
- Pathway:WP5103 - Progeria-associated lipodystrophy
- Pathway:WP5104 - Acquired partial lipodystrophy / Barraquer-Simons syndrome
- Pathway:WP5105 - Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia
- Pathway:WP5108 - Familial hyperlipidemia type 1
- Pathway:WP5109 - Familial hyperlipidemia type 2
- Pathway:WP5110 - Familial hyperlipidemia type 3
- Pathway:WP5111 - Familial hyperlipidemia type 4
- Pathway:WP5112 - Familial hyperlipidemia type 5
- Pathway:WP5114 - Nucleotide excision repair in xeroderma pigmentosum